Key result
Elevated serum ANGPTL2 levels accurately distinguished colorectal cancer patients from normal controls and were associated with advanced stage and poor prognosis.
Why the study?
Does serum ANGPTL2 level accurately diagnose colorectal cancer and predict recurrence and prognosis?
Case-Control (n=295)
Does serum ANGPTL2 level accurately diagnose colorectal cancer and predict recurrence and prognosis?
Serum ANGPTL2 is a potential novel biomarker for the early diagnosis and prediction of recurrence in colorectal cancer.
Answers are grounded in this paper and cite their sources.
Serum ANGPTL2 merits prospective validation as a colorectal cancer biomarker; observational data leave open any clinical adoption.
PURPOSE: Angiopoietin-like protein 2 (ANGPTL2) is a mediator of chronic inflammation and inflammatory carcinogenesis. The biologic and clinical significance of ANGPTL2 remains unknown in human cancer. Therefore, we investigated the function of ANGPTL2 and evaluated its clinical significance in both primary tumors and matched sera in patients with colorectal cancer. EXPERIMENTAL DESIGN: A colorectal cancer cell line was transfected with siRNA against ANGPTL2 for the assessment of its function. We examined ANGPTL2 expression in colorectal cancer tissues (n = 195) by immunohistochemistry. Finally, we screened serum ANGPTL2 levels from 32 colorectal cancers and 23 normal controls (NC), and validated these results in serum samples obtained from 195 colorectal cancers and 45 NCs by ELISA. RESULTS: Knockdown of ANGPTL2 in vitro significantly inhibited cell proliferation, migration, and invasion, whereas it enhanced anoikis. ANGPTL2 was overexpressed in colorectal cancer tissues, and was significantly associated with advanced T stage, lymph node, and liver metastasis. Likewise, serum ANGPTL2 levels in colorectal cancers were significantly higher than NCs (P < 0.01), and allowed distinguishing of colorectal cancers from NCs with high accuracy (AUC = 0.837). The subsequent validation step confirmed that serum ANGPTL2 levels in colorectal cancers were significantly higher than in NCs (P < 0.0001), and had a high AUC value (0.885) for distinguishing colorectal cancers from NCs. High serum ANGPTL2 was significantly associated with advanced T stage, lymph node and liver metastasis, early relapse, and poor prognosis in colorectal cancers. CONCLUSION: Serum ANGPTL2 is a novel diagnostic and recurrence-predictive biomarker in patients with colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Toiyama et al. (2014) conducted a case-control in Colorectal cancer (n=295). Elevated serum ANGPTL2 vs. Normal controls was evaluated on Distinguishing colorectal cancers from normal controls (AUC 0.885, p=<0.0001). Elevated serum ANGPTL2 levels accurately distinguished colorectal cancer patients from normal controls and were associated with advanced stage and poor prognosis.
Synapse has enriched 10 related papers. Consider them for comparative context: